Expression analysis of caspase-6, caspase-9 and BNIP3 in prostate cancer

Tumori

Volumn 96, Issue 1, 2010, Pages 138-142

  Yoo, Nam Jin ^a   Kim, Min Seob ^a   Park, Sang Wook ^a   Seo, Seong Il ^b   Song, Sang Yong ^b   Lee, Ji Youl ^a   Lee, Sug Hyung ^a  

^a The Catholic University of Korea   (South Korea)

^b Sungkyunkwan University   (South Korea)

Author keywords

BNIP3; Caspase 6; Caspase 9; Immunohistochemistry; Prostate cancer

Indexed keywords

CASPASE 6; CASPASE 9; PROTEIN BNIP3;

ADULT; AGE DISTRIBUTION; AGED; APOPTOSIS; ARTICLE; CANCER STAGING; CANCER TISSUE; CARCINOGENESIS; CLINICAL FEATURE; CONTROLLED STUDY; DEREGULATION; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN EXPRESSION; TISSUE MICROARRAY; TUMOR VOLUME;

ADENOCARCINOMA; ADULT; AGED; APOPTOSIS; CASPASE 6; CASPASE 9; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MEMBRANE PROTEINS; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 77950853750     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1700/479.5664     Document Type: Article

References (23)

1. Danial NN, Korsmeyer SJ: Cell death: critical control points. Cell, 116: 205-219, 2004.
2. Reed JC: Mechanisms of apoptosis. Am J Pathol, 39: 1415-1430, 2000.
3. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell, 100: 57-70, 2000.
4. VandeVelde C, Cizeau J, Dubik D, Alimonti J, Brown T, Israels S, Hakem R, Greenberg AH: BNIP3 and genetic control of necrosis-like cell death through the mitochondrial permeability transition pore.Mol Cell Biol, 20: 5454-5468, 2000.
5. Sowter HM, Ratcliffe PJ, Watson P, Greenberg AH, Harris AL: HIF-1-dependent regulation of hypoxic induction of the cell death factors BNIP3 and NIX in human tumors. Cancer Res, 61: 6669-6673, 2001.
6. Lee SH, Shin MS, Park WS, Kim SY, Kim HS, Han JY, Park GS, Dong SM, Pi JH, Kim CS, Kim SH, Lee JY, Yoo NJ: Alterations of Fas (Apo-1/CD95) gene in non-small cell lung cancer. Oncogene, 18: 3754-3760, 1999.
7. KimHS, Lee JW, Soung YH, ParkWS, KimSY, Lee JH, Park JY, Cho YG, KimCJ, Jeong SW, NamSW, KimSH, Lee JY, Yoo NJ, Lee SH: Inactivating mutations of caspase-8 gene in colorectal carcinomas. Gastroenterology, 125: 708-715, 2003.
8. Soung YH, Lee JW, Kim SY, Jang J, Park YG, Park WS, Nam SW, Lee JY, Yoo NJ, Lee SH: CASPASE-8 gene is inactivated by somatic mutations in gastric carcinomas. Cancer Res, 65: 815-821, 2005.
9. Soung YH, Lee JW, Kim HS, ParkWS, Kim SY, Lee JH, Park JY, Cho YG, Kim CJ, Park YG, Nam SW, Jeong SW, Kim SH, Lee JY, Yoo NJ, Lee SH: Inactivatingmutations of CASPASE-gene in human cancers. Oncogene, 22: 8048-8052, 2003
10. Yoo NJ, Lee JW, Kim YJ, Soung YH, Kim SY, Nam SW, Park WS, Lee JY, Lee SH: Loss of caspase-2, -6 and -7 expression in gastric cancers. APMIS, 112: 330-335, 2004.
11. Yoo NJ, Kim HS, Kim SY, ParkWS, Kim SH, Lee JY, Lee SH: Stomach cancer highly expresses both initiator and effector caspases; an immunohistochemical study. APMIS, 110: 825-832, 2002.
12. KimSY, Song SY, KimMS, Lee JY, Lee HM, Choi HY, Yoo NJ, Lee SH: Immunohistochemical analysis of Fas and FLIP in prostate cancers. APMIS, 117: 28-33, 2009.
13. Lee SH, Jeong EG, Yoo NJ, Lee SH: Mutational and expressional analysis of BNIP3, a pro-apoptotic Bcl-2member, in gastric carcinomas. APMIS, 115: 1274-1280, 2007.
14. Zhang X, Jin TG, Yang H, DeWolfWC, Khosravi-Far R, Olumi AF: Persistent c-FLIP(L) expression is necessary and sufficient to maintain resistance to tumor necrosis factorrelated apoptosis-inducing ligand-mediated apoptosis in prostate cancer. Cancer Res, 64: 7086-7091, 2004.
15. Jiang J, Ulbright TM, Zhang S, Eckert GJ, Kao C, Gardner TA, Koch MO, Eble JN, Cheng L. Fas and Fas ligand expression is elevated in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. Cancer, 95: 296-300, 2002. (Pubitemid 34787595)
16. Suzuki A, Matsuzawa A, Iguchi T: Down regulation of Bcl-2 is the first step on Fas-mediated apoptosis of male reproductive tract. Oncogene, 13: 31-37, 1996.
17. Santourlidis S,Warskulat U, Florl AR, Maas S, Pulte T, Fischer J, MüllerW, SchulzWA: Hypermethylation of the tumor necrosis factor receptor superfamily 6 (APT1, Fas, CD95/Apo-1) gene promoter at rel/nuclear factor kappaB sites in prostatic carcinoma. Mol Carcinog, 32: 36-43, 2001.
18. O'Kane HF, Watson CJ, Johnston SR, Petak I, Watson RW, Williamson KE: Targeting death receptors in bladder, prostate and renal cancer. J Urol, 175: 432-438, 2006.
19. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP: Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med, 4: 844-847, 1998.
20. Palmerini F, Devilard E, Jarry A, Birg F, Xerri L: Caspase 7 downregulation as an immunohistochemical marker of colonic carcinoma. Hum Pathol, 32: 461-467, 2001.
21. Winter RN, Kramer A, Borkowski A, Kyprianou N: Loss of caspase-1 and caspase-3 protein expression in human prostate cancer. Cancer Res, 61: 1227-1232, 2001.
22. Joseph B, Ekedahl J, Sirzen F, Lewensohn R, Zhivotovsky B: Differences in expression of pro-caspases in small cell and non-small cell lung carcinoma. Biochem Biophys Res Commun, 262: 381-387, 1999.
23. Takayama H, Takakuwa T, Dong Z, Nonomura N, Okuyama A, Nagata S, Aozasa K: Fas gene mutations in prostatic intraepithelial neoplasia and concurrent carcinoma: analysis of laser capture microdissected specimens. Lab Invest, 81: 283-828, 2001.